Anti-KCNN4 (KCa3.1, SK4) Antibody

IKCa1, IK1, Intermediate conductance Ca2+-activated K+ channel protein 4, Gardos channel
    Cat #: APC-064
    Alternative Name IKCa1, IK1, Intermediate conductance Ca2+-activated K+ channel protein 4, Gardos channel
  • Lyophilized Powder
  • Antigen Incl.
  • Type: Polyclonal
    Host: Rabbit
    Reactivity: h, m, r
      • Peptide RQVRLKHRKLREQV(C), corresponding to amino acid residues 350-363 of rat KCNN4 (Accession Q9QYW1). Intracellular, C-terminal part.
        Anti-KCNN4 (KCa3.1, SK4) Antibody
    Accession (Uniprot) Number Q9QYW1
    Peptide confirmation Confirmed by amino acid analysis and mass spectrometry.
    Homology Mouse, human, pig - identical.
    RRID AB_2039959.
    Purity Affinity purified on immobilized antigen.
    Form Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.
    Isotype Rabbit IgG.
    Storage before reconstitution The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
    Reconstitution 25 µl, 50 µl or 0.2 ml double distilled water (DDW), depending on the sample size.
    Antibody concentration after reconstitution 0.8 mg/ml.
    Storage after reconstitution The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).
    Negative control antigen storage before reconstitution Lyophilized powder can be stored intact at room temperature for 2 weeks. For longer periods, it should be stored at -20°C.
    Negative control antigen reconstitution 100 µl double distilled water (DDW).
    Negative control antigen storage after reconstitution -20°C.
    Preadsorption Control 2 µg peptide per 1 µg antibody.
    Standard quality control of each lot Western blot analysis.
    Applications: ic, if, ih, ip, wb
    May also work in: ifc*
      • Anti-KCNN4 (KCa3.1, SK4) Antibody
        Western blot analysis of HEK-293-KCa3.1 (lanes 1, 3) and K562 (lanes 2, 4) cells: 
        1,3. Anti-KCNN4 (KCa3.1, SK4) Antibody (#APC-064), (1:200).  
        2,4. Anti-KCNN4 (KCa3.1, SK4) Antibody, preincubated with the control peptide antigen.
      • Human bronchial epithelial NuLi cells (1:100) (Klein, H. et al. (2009) Am. J. Physiol. Cell Physiol. 296, C285.).
      • Rat mesenteric artery parafin-embedded sections (Hilgers, R.H. et al. (2010) J. Pharmacol. Exp. Ther. 333, 210.).
      • Normal rat cholangiocytes (NRC) (1:200) (Dutta, A.K. et al. (2009) Am. J. Physiol. Gastrointest. Liver Physiol. 297, G1009.).
    References
      • KCa3.1 (KCNN4, SK4) is a member of the Ca2+ activated K+ channel family that shares the characteristic of being activated by intracellular Ca2+. The channel has an intermediate conductance, is voltage insensitive and is activated by Ca2+ in the submicromolar range. The channel has a similar topology to that of KV channels, that is, six transmembrane domains and intracellular N- and C-termini. 

        KCa3.1 is widely expressed in epithelial, endothelial and cells of hematopoietic origin. In erythrocytes (red blood cells) it has been identified as the molecular correlate of the so-called Gardos channel.  

        The functional role of the channel is to set the cell membrane potential at negative values so as to aid in the electrochemical transport of other ions such as Cl- and Ca2+. Indeed, KCa3.1 has a key role in sustaining the Ca2+ influx in activated T lymphocytes and in regulating Cl- secretion from colon epithelium. Therefore, specific blockers of the KCa3.1 channel have been proposed for the treatment of several diseases including autoimmune diseases, secretory diarrhea and sickle cell anemia.

    Application key:

    CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot

    Species reactivity key:

    H- Human, M- Mouse, R- Rat
    Last update: 24/01/2020

    Anti-KCNN4 (KCa3.1, SK4) Antibody (#APC-064) is a highly specific antibody directed against an epitope of the rat protein. The antibody can be used in western blot analysis, immunocytochemistry, immunohistochemistry, and immunoprecipitation applications. It has been designed to recognize KCNN4 from human, rat, and mouse samples.

    For research purposes only, not for human use
    Citations
      • Human airway epithelial cfbe41o cells (1:300).
        Klein, H. et al. (2016) PLoS ONE 11, e0153665.
      • Human airway epithelial cfbe41o cells (1:100).
        Klein, H. et al. (2016) PLoS ONE 11, e0153665.
      • Human bronchial epithelial NuLi cells (1:100).
        Klein, H. et al. (2009) Am. J. Physiol. Cell Physiol. 296, C285.
      • Human chorionic plate arterial smooth muscle cell sections (8 µg/ml).
        Brereton, M.F. et al. (2013) PLoS ONE 8, e57451.
      • Rat mesenteric artery parafin-embedded sections.
        Hilgers, R.H. et al. (2010) J. Pharmacol. Exp. Ther. 333, 210.
      • Human chorionic plate arterial smooth muscle cells (10 µg/ml).
        Brereton, M.F. et al. (2013) PLoS ONE 8, e57451.
      • Normal rat cholangiocytes (NRC) (1:200).
        Dutta, A.K. et al. (2009) Am. J. Physiol. Gastrointest. Liver Physiol. 297, G1009.
      • Kirby, B.S. et al. (2013) PLoS ONE 8, e54849.
      • Bagher, P. et al. (2012) Proc. Natl. Acad. Sci. U.S.A. 109, 18174.
      • Bouhy, D. et al. (2011) J. Neurosci. 31, 16298.
      • Longden, T.A. et al. (2011) Br. J. Pharmacol 164, 922.
      • Ohya, S. et al. (2011) J. Biol. Chem. 286, 16940.
      • Su, X.L. et al. (2011) J. Mol. Cell. Cardiol. 51, 51.
      • Earley, S. et al. (2009) Circ. Res. 104, 987.
      • Hirota, C.L. et al. (2009) Br. J. Pharmacol. 156, 1085.
      • Feng, J. et al. (2008) Circulation 118, S46.
      • Lauf, P.K. et al. (2008) Am. J. Physiol. Cell Physiol. 294, C820.
      • Trinh, N.T. et al. (2008) Am. J. Physiol. Lung Cell Mol. Physiol. 295, L866.
      • Kaushal, V. et al. (2007) J. Neurosci. 27, 234.
      • Dong, H. et al. (2006) Am. J. Physiol. Gastrointest. Liver Physiol. 291, G1120.
      • McNeish, A.J. et al. (2006) Stroke 37, 1277.
      • Sandow, S.L. et al. (2006) J. Anat. 209, 689.
      • Srivastava, S. et al. (2006) Mol. Cell 24, 665.
      • Ubels, J.L. et al. (2006) Invest. Ophtalmol. Vis. Sci. 47, 1876.
    Related Products